Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunxia Su

Showing results (81-90 of 223) with videos related to

Pageof 23
Sort By:
Oncotarget|October 6, 2017
Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patientsTao Jiang, Aiwu Li, Chunxia Su, et al.
International Journal of Clinical and Experimental Pathology|July 21, 2015
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancerChunxia Su, Ying Xu, Xuefei Li, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancerXin Yu, Xiangling Chu, Yan Wu, et al.
Cancer Medicine|April 25, 2019
Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAFXibin Zhuang, Chao Zhao, Jiayu Li, et al.
Frontiers in Microbiology|August 15, 2020
Past, Present, and Future of Gastrointestinal Microbiota Research in CatsYang Lyu, Chunxia Su, Adronie Verbrugghe, et al.
Discover Oncology|July 29, 2025
A web-based prediction model for brain metastasis in non-small cell lung cancer patientsJianing Chen, Li Wang, Li Liu, et al.
Clinical and Translational Medicine|June 22, 2020
Pan-cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatmentTao Jiang, Qingzhu Jia, Wenfeng Fang, et al.
Journal of Immunology Research|December 21, 2020
Lycium barbarum Polysaccharides Promote Maturity of Murine Dendritic Cells through Toll-Like Receptor 4-Erk1/2-Blimp1 Signaling PathwayXiangguo Duan, Yaru Lan, Xiaoyu Zhang, et al.
Clinical Lung Cancer|November 28, 2017
Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung CancerTao Jiang, Hongcheng Liu, Meng Qiao, et al.
Translational Lung Cancer Research|May 19, 2020
Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastasesJuan Zhou, Fei Zhou, Xiangling Chu, et al.
Pageof 23

Showing results (81-90 of 223) with videos related to

Sort By:
Pageof 23
Oncotarget|October 6, 2017
Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patientsTao Jiang, Aiwu Li, Chunxia Su, et al.
International Journal of Clinical and Experimental Pathology|July 21, 2015
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancerChunxia Su, Ying Xu, Xuefei Li, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancerXin Yu, Xiangling Chu, Yan Wu, et al.
Cancer Medicine|April 25, 2019
Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAFXibin Zhuang, Chao Zhao, Jiayu Li, et al.
Frontiers in Microbiology|August 15, 2020
Past, Present, and Future of Gastrointestinal Microbiota Research in CatsYang Lyu, Chunxia Su, Adronie Verbrugghe, et al.
Discover Oncology|July 29, 2025
A web-based prediction model for brain metastasis in non-small cell lung cancer patientsJianing Chen, Li Wang, Li Liu, et al.
Clinical and Translational Medicine|June 22, 2020
Pan-cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatmentTao Jiang, Qingzhu Jia, Wenfeng Fang, et al.
Journal of Immunology Research|December 21, 2020
Lycium barbarum Polysaccharides Promote Maturity of Murine Dendritic Cells through Toll-Like Receptor 4-Erk1/2-Blimp1 Signaling PathwayXiangguo Duan, Yaru Lan, Xiaoyu Zhang, et al.
Clinical Lung Cancer|November 28, 2017
Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung CancerTao Jiang, Hongcheng Liu, Meng Qiao, et al.
Translational Lung Cancer Research|May 19, 2020
Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastasesJuan Zhou, Fei Zhou, Xiangling Chu, et al.
Pageof 23